Condition: Primary Hyperparathyroidism · Hypercalcemia · Sponsor: Joseph Sferra
Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.
This description comes directly from the study's public registry record.
Leah Stevenson, MS · 419-291-3491 · leah.stevenson@promedica.org
Dawn Muskiewicz, MS · 419-291-7517 · dawn.muskiewicz@promedica.org
Always discuss trial participation with your own doctor first.
| ProMedica Toledo Hospital | Toledo, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03935984